American Cancer Society (ACS) Journals shared a post on LinkedIn:
“Could altering the daily timing of immunotherapy improve survival in people with cancer?
A new study appearing today in CANCER suggests that receiving anticancer immunotherapy earlier in the day may help individuals with cancer live longer. Researchers found that patients who received immunochemotherapy before 3:00 pm received the most benefits from treatment. Patients who received treatment before 3:00 pm experienced significantly longer progression-free survival (length of time without cancer progression) and overall survival compared with those treated later.
After adjusting for influencing factors, earlier time of day of administration was associated with a 52% lower risk of cancer progression and a 63% lower risk of death.
‘Adjusting infusion timing is a straightforward and easily implementable intervention that can be adopted across diverse healthcare settings without additional cost,’ said senior author Yongchang Zhang, MD, of Central South University, in a press release. ‘This study has immediate clinical applicability and the potential to transform current treatment protocols for small cell lung cancer.’
Title: Overall survival according to time-of-day of immunochemotherapy for extensive-stage small cell lung cancer
Authors: Zhe Huang, Zhaohui Ruan, Shidong Xu, Nachuan Zou, Li Deng, Huan Yan, Jiacheng Dai, Jun Deng, Xue Chen, Jing Wang, Hua Xiang, Liang Zeng, Gang Yin, Yongchang Zhang
You can read the full article in Cancer.
More posts from American Cancer Society Journals.